Want to see MDWD full AI Analyst Report?
MDWD Stock Chart & Stats
$12.70
$0.22(1.55%)
At close: 4:00 PM EDT
$12.70
$0.22(1.55%)
Day’s Range― - ―
52-Week Range$11.84 - $19.93
Previous Close$14.45
Volume52.10K
Average Volume (3M)83.19K
Market Cap
$163.96M
Enterprise Value$163.59M
Total Cash (Recent Filing)$35.34M
Total Debt (Recent Filing)$9.54M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 17, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding12,910,278
10 Day Avg. Volume74,263
30 Day Avg. Volume83,192
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.81
Price to Sales (P/S)12.38
P/FCF Ratio-10.48
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue13.79
Enterprise Value/Gross Profit89.20
Enterprise Value/Ebitda-8.61
Forecast
1Y Price Target
$29.60Price Target Upside133.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.19
Revenue Forecast (FY)$23.67M
Bulls Say, Bears Say
Bulls Say
EscharEx Phase III AdvancingProgress in a large, late-stage trial supports MediWound’s long-term pipeline development and could broaden its wound-care opportunity beyond burns. Defined enrollment milestones provide a measurable path toward clinical evidence for EscharEx in chronic venous leg ulcers.
NexoBrid Adoption ExpandingRecord partner-reported quarterly revenue, hospital unit sales, and ordering-center activity indicate growing U.S. utilization of NexoBrid. Broader burn-center adoption can strengthen the commercial base and improve the product’s long-term position in specialized burn care.
Government-backed CollaborationThe MSA connects MediWound to a long-duration, government-backed program and creates an additional development-related revenue channel. Such collaboration can support next-generation NexoBrid applications, diversify funding sources, and expand strategic relevance in trauma care.
Bears Say
Declining Revenue And Weak MarginsPersistent revenue contraction and low gross profitability indicate that MediWound has not yet achieved dependable operating leverage. Deep losses reduce internal funding capacity and make sustained improvement dependent on commercial growth, better product economics, or external financing.
Persistent Cash BurnNegative operating and free cash flow show that the current business does not yet self-fund operations or development investment. Continued cash consumption can constrain clinical execution and strategic flexibility, particularly while EscharEx and manufacturing programs require substantial spending.
Manufacturing Capacity ConstraintsRegulatory-tied facility work delays the point at which MediWound can access expanded commercial capacity. Until approval and supply availability improve, constrained production may limit NexoBrid sales growth, inventory availability, and the company’s ability to capture demand.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $11.84 and its highest was $19.93 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $163.96M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Aug 13, 2026. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.762 by -$0.008.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.71.
How many shares outstanding does Mediwound have?
Mediwound has 12,910,278 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.762. Following the earnings report the stock price went down -2.732%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.60 (133.07% Upside)
$29.60 (133.07% Upside)
Blogger Sentiment
Neutral
MDWD Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 3.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $75.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.42%
12-Months-Change
Fundamentals
Return on Equity
-47.24%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful strategic and operational milestones — advancing EscharEx Phase III enrollment, an expanded $1.05B U.S. market assessment, a new MSA with Vericel tied to BARDA funding, government-sponsored next-generation NexoBrid programs, and strengthened U.S. commercial signals for NexoBrid. However, the company reported sharp year-over-year revenue declines (Q2 down ~45.6%, H1 down ~52.6%), substantial margin compression, rising R&D and operating losses, a notable cash decline to $36M and $20M H1 cash burn, and ongoing manufacturing capacity constraints with regulatory-tied timelines. Overall, positives around pipeline progress and government-backed programs are balanced by near-term financial weakness and execution/timing risks.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$29.60
▲(133.07% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Corbus Pharmaceuticals
―
Verrica Pharmaceuticals
―
Humacyte
―
Ownership Overview
0.73% Insiders
5.62% Mutual Funds
2.29% Other Institutional Investors
86.11% Public Companies and
Individual Investors